Dec 2 (Reuters) -- The U.S. Food and Drug Administration's drug evaluation chief, Richard Pazdur, is set to retire just weeks after taking the new role, a spokesperson for the health regulator said on Tuesday. Pazdur, the agency's veteran oncology chief, took over the role on November 11, replacing George Tidmarsh after he resigned amid serious concerns about his personal conduct. "We respect Dr. Pazdur's decision to retire and honor his 26 years of distinguished service at the FDA," the spokesperson said in a statement.
"[Pazdur] is one of the most effective and creative regulators in FDA history. With so much attrition already, we're left with a team with very little experience making major decisions," former FDA Commissioner Robert Califf said about the move.
Drudge Retort Headlines
U.S. President Posts 160 Rants Last Night (173 comments)
White House Confirms Hegseth Ordered 2nd Strike (93 comments)
Backlash Growing Against Home Deport (60 comments)
How Fraud Swamped Minnesota's Social Services System on Tim Walz's Watch (60 comments)
Trump Frees Fraudster Just Days Into 7-Year Sentence (22 comments)
Trump Says He Will Pardon Ex-Honduras President (22 comments)
Pregnant Mother Died After She Couldn't Get an Abortion in Texas (19 comments)
New Senate Bill Seeks to Outlaw Dual Citizenship (15 comments)
Ex-President Whom Trump Plans to Pardon Flooded America With Cocaine (15 comments)
Why Is Trump Hiding Economic Reports? (11 comments)